Market Summery:
Peptic Ulcer Drugs
Market Size was valued at USD 4.2 billion in 2022 and to grow from USD
4.4 Billion in 2023 to USD 5.8 billion by 2030, exhibiting a compound annual
growth rate (CAGR) of 4.80% during the forecast period (2023 - 2030).
Market Highlights
The
Peptic Ulcer Drugs Market, primarily focusing on stomach ulcer medication, is
witnessing significant growth due to several factors. Stomach ulcers, also
known as peptic ulcers, are painful sores that develop in the lining of the
stomach, small intestine, or esophagus. The rising prevalence of
gastrointestinal disorders, including peptic ulcers, is a key driving factor
for the market growth. Factors such as stress, unhealthy lifestyle habits, and
the widespread use of nonsteroidal anti-inflammatory drugs (NSAIDs) contribute
to the increasing incidence of stomach ulcers, thereby fueling the demand for
effective medications.
In
response to this growing demand, pharmaceutical companies are actively
developing innovative stomach ulcer
medication to provide relief to patients. These medications aim to alleviate
symptoms, promote ulcer healing, and prevent recurrence. Proton pump inhibitors
(PPIs), histamine receptor antagonists (H2 blockers), and antibiotics are among
the commonly prescribed drugs for stomach ulcers. Additionally, advancements in
drug delivery technologies are enhancing the efficacy and safety profile of
these medications, further propelling market expansion. Overall, the Peptic
Ulcer Drugs Market, driven by the increasing prevalence of stomach ulcers and
ongoing research and development efforts, is poised for substantial growth in
the coming years, offering promising prospects for pharmaceutical companies and
healthcare providers alike.
Competitive Dashboard
Daiichi
Sankyo Company Limited,
Novartis
AG,
Acetelion
Ltd.,
Sanofi
S.A.,
Boehringer
Ingelheim,
Astra
Zeneca plc,
Takeda
Pharmaceuticals Company Limited,
Ranbaxy
Laboratories Limited, Inc.,
Pfizer
Inc.,
Eumedica
Pharmaceuticals, and
Helicure
AB,
are
some of the key peptic ulcer drugs
Companies in global market.
Segmental Analysis
The
global peptic ulcer drugs market has been segmented on the basis of
pharmacological class into proton pump inhibitors (PPIs), anti-histamines, H2
antagonists, antacids, antibiotics and others.
The
market is segmented by clinical application into gastric ulcers, duodenal
ulcer, and esophageal ulcer.
Regional Overview
Geographically,
the global peptic ulcer market can be segmented into North America, Latin
America, Europe, Asia Pacific, and Middle East & Africa.
It
is estimated that North America will lead the global demand for peptic ulcers,
accounting for the highest share over the expected period. A increase in
non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and the
understanding of peptic ulcer treatment options are factors that are expected
to boost the growth demand for peptic ulcer drugs in the North American region.
North America 's market rise is due to an rise in the prevalence of stomach
cancer in the country.
The
second largest share of the demand for peptic ulcer drugs in Europe is partly
due to the simple availability of effective treatment alternatives for peptic
ulcers in the country.
During
the forecast period, the Asia Pacific market is projected to develop at a
higher growth rate. Because of the large population, growth in health
consciousness and high prevalence of lifestyle-related diseases, stomach
infections caused by H, it is the most lucrative market. Pylori, as well as
cancer.
Related reports-
For more information, Please Visit us @ Market
Research Future
No comments:
Post a Comment